Flexion Therapeutics, Inc. (FLXN)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Flexion Therapeutics, Inc. (FLXN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Flexion Therapeutics, Inc. ever had a stock split?
Flexion Therapeutics, Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Michael Clayman CEO | NASDAQ (NMS) Exchange | 44053A523 CUSIP |
| US Country | 257 Employees | 27 Jul 2026 Last Dividend | - Last Split | - IPO Date |
Overview
Flexion Therapeutics, Inc. is a biopharmaceutical company with a focused mission to discover, develop, and commercialize innovative therapies aimed at treating musculoskeletal conditions. Since its inception in 2007, the company has been dedicated to addressing the needs of patients suffering from such conditions, primarily focusing on the development of advanced treatments that offer pain relief and improve quality of life. Based in Burlington, Massachusetts, Flexion Therapeutics combines cutting-edge research with a patient-centered approach to offer novel solutions in the market of musculoskeletal care.
Products and Services
- ZILRETTA
- FX201
- FX301
An intra-articular injection specifically designed for the management of osteoarthritis pain in the knee. ZILRETTA is available in the United States and stands out as Flexion Therapeutics’ flagship product. It represents a significant advancement in osteoarthritis treatment, aiming to provide patients with long-lasting pain relief through a single injection.
A gene therapy product candidate in development, aimed at stimulating the production of interleukin-1 receptor antagonist, an anti-inflammatory protein. FX201 is designed for the treatment of osteoarthritis of the knee, providing a novel approach to pain management by potentially altering the disease's progression and offering long-term relief.
Another innovative product candidate in Flexion’s pipeline is FX301, a NaV1.7 inhibitor formulated for the management of post-operative pain. Administered locally, FX301 aims to offer targeted pain relief without the systemic effects associated with traditional pain management drugs, showcasing Flexion’s commitment to developing safer, more effective pain management options.
